Amendment: SEC Form SC 13G/A filed by Fulcrum Therapeutics Inc.
$FULC
Biotechnology: Pharmaceutical Preparations
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/29/2025 | $4.00 → $12.00 | Neutral → Buy | H.C. Wainwright |
| 5/23/2025 | $12.00 | Market Perform → Outperform | Leerink Partners |
| 5/15/2025 | $10.00 | Neutral → Overweight | Cantor Fitzgerald |
| 9/13/2024 | $17.00 → $4.00 | Buy → Neutral | H.C. Wainwright |
| 9/12/2024 | $15.00 → $4.00 | Outperform → Sector Perform | RBC Capital Mkts |
| 9/12/2024 | $4.00 | Outperform → Market Perform | Leerink Partners |
| 9/12/2024 | $10.00 → $2.00 | Neutral → Underperform | BofA Securities |
| 9/12/2024 | Buy → Hold | Stifel |
CAMBRIDGE, Mass., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to new employees. Fulcrum granted stock options to purchase shares of the company's common stock pursuant to the company's 2022 Inducement Stock Incentive Plan, as amended, or the plan, as an inducement material to the new employees entering into employment with Fulcrum in accordance with Nasdaq Listing Rule 5635(c)(4). Fulcrum granted the new employees an aggregate of 36,400
― Announced results from the 12 mg dose cohort (n=16) of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD); pociredir was generally well-tolerated with no treatment-related serious adverse events (SAEs) ― ― Observed robust and rapid pan-cellular increases in fetal hemoglobin (HbF); meaningful improvements in key markers of hemolysis and anemia; encouraging trends in vaso-occlusive crises (VOCs) ― ― On track to provide clinical data from the 20 mg dose cohort by the end of 2025 ― ― Ended Q2 2025 with $214.1 million in cash, cash equivalents, and marketable securities; cash runway into 2028 ― CAMBRIDGE, Mass., July 29, 2025 (GLOBE NEWSWI
― Robust and clinically meaningful absolute mean fetal hemoglobin (HbF) induction of 8.6% from baseline at 12 weeks of treatment; 7 of 16 patients achieved absolute HbF levels greater than 20% ― ― Evidence of pan-cellular induction of HbF based on an increase in F-cells (red blood cells containing HbF) from a mean of 34% at baseline to 67% at 12 weeks of treatment ― ― Meaningful improvements in key markers of hemolysis coupled with a 0.9 g/dL mean increase in total hemoglobin (Hb) ― ― Encouraging trends in vaso-occlusive crisis (VOC) reduction compared to baseline ― ― Pociredir continued to be generally well-tolerated with no treatment-related serious adverse events (SAEs); all treatment
SCHEDULE 13G/A - Fulcrum Therapeutics, Inc. (0001680581) (Subject)
10-Q - Fulcrum Therapeutics, Inc. (0001680581) (Filer)
8-K - Fulcrum Therapeutics, Inc. (0001680581) (Filer)
H.C. Wainwright upgraded Fulcrum Therapeutics from Neutral to Buy and set a new price target of $12.00 from $4.00 previously
Leerink Partners upgraded Fulcrum Therapeutics from Market Perform to Outperform and set a new price target of $12.00
Cantor Fitzgerald upgraded Fulcrum Therapeutics from Neutral to Overweight and set a new price target of $10.00
4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
― Robust and clinically meaningful absolute mean fetal hemoglobin (HbF) induction of 8.6% from baseline at 12 weeks of treatment; 7 of 16 patients achieved absolute HbF levels greater than 20% ― ― Evidence of pan-cellular induction of HbF based on an increase in F-cells (red blood cells containing HbF) from a mean of 34% at baseline to 67% at 12 weeks of treatment ― ― Meaningful improvements in key markers of hemolysis coupled with a 0.9 g/dL mean increase in total hemoglobin (Hb) ― ― Encouraging trends in vaso-occlusive crisis (VOC) reduction compared to baseline ― ― Pociredir continued to be generally well-tolerated with no treatment-related serious adverse events (SAEs); all treatment
CAMBRIDGE, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, will host a conference call and webcast on Tuesday, July 29, 2025 beginning at 8:00 a.m. ET to present topline results from the 12 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease. Members of Fulcrum management will be joined by Dr. Sheinei Alan, Director of the Inova Fairfax Adult Sickle Cell Program, and Assistant Professor at UVA School of Medicine Inova Campus, and Dr. Wally Smith, Director at the VC
― Enrollment complete in the 12 mg dose cohort (n=16) of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD); initiated the 20 mg dose cohort ― ― On track to provide clinical data from the 12 mg dose cohort in early Q3 2025 and the 20 mg dose cohort by the end of 2025 ― ― Ended Q1 2025 with $226.6 million in cash, cash equivalents, and marketable securities; cash runway into at least 2027 ― ― Conference call and webcast scheduled for 8:00 a.m. ET today ― CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improv
CAMBRIDGE, Mass., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced the appointment of Isabel Kalofonos as chief commercial officer and Heather Faulds as chief regulatory affairs & quality assurance officer. Together, Ms. Kalofonos and Ms. Faulds will be instrumental in advancing losmapimod towards a New Drug Application (NDA) submission and preparing for commercial launch. "I am excited to welcome Isabel to our leadership team as we continue to advance towards the potential approval a
―Industry veteran with late-stage clinical development, medical affairs, and regulatory experience; well-positioned to advance losmapimod towards a potential regulatory submission and approval ― ― Interim Chief Medical Officer, Iain Fraser, MBChB, DPhil, will continue to serve on Fulcrum's executive leadership team as senior vice president (SVP) of early development ― CAMBRIDGE, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced the appointment of Patrick Horn, M.D., Ph.D., as
CAMBRIDGE, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced the appointment of Alan A. Musso as chief financial officer, effective August 7, 2023. A 30-year veteran in the life sciences industry, Mr. Musso has held numerous financial and operational leadership positions over the course of his career. "We are delighted to welcome Alan to our executive leadership team," said Alex C. Sapir, president and chief executive officer at Fulcrum Therapeutics. "Alan's wealth of industry experience and impressive track record
SC 13G/A - Fulcrum Therapeutics, Inc. (0001680581) (Subject)
SC 13G/A - Fulcrum Therapeutics, Inc. (0001680581) (Subject)
SC 13G/A - Fulcrum Therapeutics, Inc. (0001680581) (Subject)